Philadelphia-based biotech innovator Vivodyne has secured a substantial $38M in seed funding. Leading the investment round is Khosla Ventures, with notable backers including Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures, marking a significant vote of confidence in the company.

The injection of capital empowers Vivodyne to expedite the development of their groundbreaking AI platform. This platform's primary endeavor is to revolutionize how novel therapeutic targets are discovered and to enhance predictions in patient treatment outcomes.